ERBB2 and obesity due to melanocortin 4 receptor deficiency: Ligorio et al. highlighted that overweight and obesity negatively affect prognosis in HER2-positive breast cancer, potentially by fostering systemic inflammation and resistance to anti-HER2 therapies [17].